News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Sanofi-Aventis (France) Drops After FDA Staff Comments on Acomplia
June 12, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS (Reuters) - Sanofi-Aventis shares fell as much as 1.7 percent on Tuesday as investors reacted warily to a U.S. health review of anti-obesity pill Acomplia, highlighting side-effects such as suicidal tendencies.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Vaccines
American Academy of Pediatrics Contradicts CDC, Recommends COVID-19 Shot for Kids
August 20, 2025
·
2 min read
·
Tristan Manalac
Podcast
MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum
August 20, 2025
·
2 min read
·
Heather McKenzie
FDA
Leaked MAHA Strategy Emphasizes Vaccine Overhaul, Streamlined Access to Novel Therapies
August 18, 2025
·
3 min read
·
Heather McKenzie
Approvals
Precigen Wins First FDA Immunotherapy Nod for Recurrent Respiratory Papillomatosis
August 15, 2025
·
1 min read
·
Tristan Manalac
